Implementation of hepatitis B vaccine in high-risk young adults with waning immunity
Authors:
Open Access
- 20 August 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0202637
Abstract
Universal hepatitis B (HB) vaccination among Thai newborns was initiated in 1992. The first dose of the monovalent HB vaccine was given at birth, then at months 2 and 6 simultaneously with the diphtheria-tetanus-pertussis whole-cell (DTPw) vaccine. In 2008, Thailand replaced the monovalent HB vaccine at months 2 and 6 with a combined DTP-HB given at months 2, 4, and 6, with an added monovalent HB vaccine at month 1 for infants whose mothers were HBV carriers. Despite this rigorous HB vaccination schedule, vaccinated infants who are now adolescents do not possess a protective level of anti-HB surface antigen (anti-HBs) (≥10 mIU/ml). Thus, many young adults may be rendered susceptible to HB infection. Our objective was to determine how HB booster vaccination may benefit high-risk adolescents. We evaluated the serological records of a cohort of medical students (n = 291), which showed that 271 students (93.1%) possessed anti-HBs less than the accepted protective level (<10 mIU/ml) and subsequently received the HB vaccine booster prior to medical school enrollment. We then examined the anti-HB surface antibody (anti-HBs) in 216 individuals six weeks after they were immunized. We found that 61%, 88%, and 94% of individuals with pre-booster anti-HBs of <1 mIU/ml, 1-<3 mIU/ml, and 3-<10 mIU/ml achieved protective anti-HBs, respectively. Post-booster geometric mean titers were 305, 513, and 1,929 mIU/ml in these groups and correlated with pre-booster anti-HBs titers. These data suggest that medical students with known anti-HBs <1 mIU/ml will benefit from 3 doses of HB vaccine at 0, 1, and 6 months. Students with anti-HBs 1-<10 mIU/ml would benefit from an HB vaccine booster without further anti-HBs evaluation.Keywords
Funding Information
- The Center of Excellence in Clinical Virology (GCE 58-014-30-004)
- Research Chair Grant from NSTDA (P-15-50004)
- Rachadapisek Sompote Fund of Chulalongkorn University for postdoctoral fellowships
- Rachadapisek Sompote Fund of Chulalongkorn University for postdoctoral fellowships
This publication has 30 references indexed in Scilit:
- Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothersHuman Vaccines & Immunotherapeutics, 2012
- Hepatitis B and the Need for a Booster DoseClinical Infectious Diseases, 2011
- Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity regionJournal of Viral Hepatitis, 2011
- Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccinationVaccine, 2009
- Long‐Term Benefit of Hepatitis B Vaccination among Children in Thailand with Transient Hepatitis B Virus Infection Who Were Born to Hepatitis B Surface Antigen–Positive MothersThe Journal of Infectious Diseases, 2009
- Long-Term Humoral and Cellular Immune Response to Hepatitis B Vaccine in High-Risk Children 18–20 Years After Neonatal ImmunizationViral Immunology, 2009
- Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of ageVaccine, 2008
- Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunizationTropical Medicine & International Health, 2006
- Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigenThe Journal of Pediatrics, 1995
- A 9-Year Follow-Up Study of the Immunogenicity and Long-Term Efficacy of Plasma-Derived Hepatitis B Vaccine in High-Risk Chinese NeonatesClinical Infectious Diseases, 1993